Literature DB >> 3349464

Uptake kinetics of monoclonal antibodies by human malignant melanoma multicell spheroids.

C S Kwok1, S E Cole, S K Liao.   

Abstract

Detailed uptake kinetics by multicell spheroids of three tumor associated monoclonal antibodies was investigated. The spheroids were established from a human melanoma cell line and the human colon adenocarcinoma cell line HT29 as in vitro models of poorly vascularized micrometastases in vivo. The selected antibodies 96.5, 140.240, and OST15 showed a wide range of reactivity against the melanoma cell but they all had negligible binding with the colon cancer cell. Uptake of the antibodies by small spheroids (about 300 micron diameter) was generally sigmoidal in shape with respect to incubation time, and amount of uptake followed the same trend of immunoreactivity of the antibodies with single cells. The correlation was weaker for spheroids with diameter greater than 500 micron presumably due to the increasing size of the necrotic core. By varying the concentration of the antibodies in the incubation medium from tracer dose (0.2 microgram/ml) to a higher dose (3 micrograms/ml), negligible changes in the amount of antibodies bound with their target spheroids were observed. Nonspecific binding between antibodies and spheroids, however, resulted in proportional increase in uptake.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3349464

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Quantification of transport and binding parameters using fluorescence recovery after photobleaching. Potential for in vivo applications.

Authors:  E N Kaufman; R K Jain
Journal:  Biophys J       Date:  1990-10       Impact factor: 4.033

2.  Measurement of mass transport and reaction parameters in bulk solution using photobleaching. Reaction limited binding regime.

Authors:  E N Kaufman; R K Jain
Journal:  Biophys J       Date:  1991-09       Impact factor: 4.033

Review 3.  Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors:  C H Ford; V J Richardson; V S Reddy
Journal:  Indian J Pediatr       Date:  1990 Jan-Feb       Impact factor: 1.967

4.  Diffusion of an anti-transferrin receptor antibody in cultured murine melanoma cell layers.

Authors:  V Vijaykumar; E M Topp
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

5.  Complement-mediated killing of microtumors in vitro.

Authors:  J Hakulinen; S Meri
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

6.  Analysis of the Equilibrium Phase in Immune-Controlled Tumors Provides Hints for Designing Better Strategies for Cancer Treatment.

Authors:  Kevin Atsou; Sokchea Khou; Fabienne Anjuère; Véronique M Braud; Thierry Goudon
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

7.  Quantitative autoradiographic evaluation of the influence of protein dose on monoclonal antibody distribution in human ovarian adenocarcinoma xenografts.

Authors:  F E Yang; R S Brown; K F Koral; A C Clavo; G A Jackson; R L Wahl
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

8.  Penetration of anti-melanoma immunotoxin into multicellular tumor spheroids and cell kill effects.

Authors:  T Kikuchi; T Ohnuma; J F Holland; L E Spitler
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  Homogeneous penetration but heterogeneous binding of antibodies to carcinoembryonic antigen in human colon carcinoma HT-29 spheroids.

Authors:  J Carlsson; E Daniel-Szolgay; G Frykholm; B Glimelius; A Hedin; B Larsson
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

10.  Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.

Authors:  T Saga; R D Neumann; T Heya; J Sato; S Kinuya; N Le; C H Paik; J N Weinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.